Screening by compound activity could accelerate drug discovery
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
List view / Grid view
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
1 March 2021 | By Bruker Scientific, LLC
Watch our free on-demand webinar that focuses on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology.
26 February 2021 | By Domain Therapeutics
Watch our on-demand webinar which focused on the progress achieved in G protein-coupled receptor (GPCR) therapeutic antibody-based discovery and development.
According to a new report, the high-throughput screening market will increase at a CAGR of 11.5 percent from 2020 to 2025.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
Phenotypic profiling identifies biomarkers and mechanisms of toxicity.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
A high-throughput screening assay for macrocyclic peptides with affinity to ubiquitin has been created by researchers.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.